Ciraparantag effectively reverses anticoagulantion with apixaban or rivaroxaban in healthy adults

Ciraparantag is a small synthetic molecule that binds directly to direct factor Xa inhibitors, direct thrombin inhibitors, and unfractionated and low-molecular-weight heparin (LMWH).

A new study by Dr Jack Ansell and team Hofstra Northwell School of Medicine reported that Ciraparantag provided a dose-related reversal of anticoagulation induced by steady-state dosing of apixaban or rivaroxaban and all doses of Ciraparantag were tolerated. The study is published in European Heart Journal.

The objective of the study was to evaluate the efficacy and safety of ciraparantag to reverse anticoagulation induced by apixaban or rivaroxaban in healthy elderly adults.

The study was two randomized, placebo-controlled, dose-ranging trials conducted in healthy subjects aged 50–75 years. Subjects received apixaban (Study 1) 10 mg orally twice daily for 3.5 days or rivaroxaban (Study 2) 20 mg orally once daily for 3 days. At steady-state anticoagulation subjects were randomized 3:1 to a single intravenous dose of ciraparantag (Study 1: 30, 60, or 120 mg; Study 2: 30, 60, 120, or 180 mg) or placebo. Efficacy was evaluated based on correction of the whole blood clotting time (WBCT) at multiple timepoints over 24 h. Subjects and technicians performing WBCT testing were blinded to treatment.